1
|
Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das B, Gosain M, Ayushi, Singh J, Anbalagan A, Shaman H, Pargai K, Mehdi F, Das SJ, Kahlon N, Singh S, Kshetrapal P, Wadhwa N, Pandey AK, Bhatnagar S, Garg PK. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months. EBioMedicine 2022; 78:103938. [PMID: 35305396 PMCID: PMC8923830 DOI: 10.1016/j.ebiom.2022.103938] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 02/23/2022] [Accepted: 03/01/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Rapid spread of the omicron SARS-CoV-2 variant despite extensive vaccination suggests immune escape. The neutralising ability of different vaccines alone or with natural SARS-CoV-2 infection against omicron is not well-known. METHODS In this cross-sectional study, we tested the ability of vaccine and natural infection induced antibodies to neutralise omicron variant in a live virus neutralisation assay in four groups of individuals: (i) ChAdOx1 nCoV-19 vaccination, (ii) ChAdOx1 nCoV-19 vaccination plus prior SARS-CoV-2 infection, (iii) vaccination with inactivated virus vaccine (BBV152), and (iv) BBV152 vaccination plus prior SARS-CoV-2 infection. Primary outcome was fold-change in virus neutralisation titre against omicron compared with ancestral virus. FINDINGS We included 80 subjects. The geometric mean titre (GMT) of the 50% focus reduction neutralisation test (FRNT50) was 380·4 (95% CI: 221·1, 654·7) against the ancestral virus with BBV152 vaccination and 379·3 (95% CI: 185·6, 775·2) with ChAdOx1 nCov-19 vaccination alone. GMT for vaccination plus infection groups were 806·1 (95% CI: 478·5, 1357·8) and 1526·2 (95% CI: 853·2, 2730·0), respectively. Against omicron variant, only 5 out of 20 in both BBV152 and ChAdOx1 nCoV-19 vaccine only groups, 6 out of 20 in BBV152 plus prior SARS-CoV-2 infection group, and 9 out of 20 in ChAdOx1 nCoV-19 plus prior SARS-CoV-2 infection group exhibited neutralisation titres above the lower limit of quantification (1:20) suggesting better neutralisation with prior infection. A reduction of 26·6 and 25·7 fold in FRNT50 titres against Omicron compared to ancestral SARS-CoV-2 strain was observed for individuals without prior SARS-CoV-2 infection vaccinated with BBV152 and ChAdOx1 nCoV-19, respectively. The corresponding reduction was 57·1 and 58·1 fold, respectively, for vaccinated individuals with prior infection. The 50% neutralisation titre against omicron demonstrated moderate correlation with serum anti-RBD IgG levels [Spearman r: 0·58 (0·41, 0·71)]. INTERPRETATION Significant reduction in the neutralising ability of both vaccine-induced and vaccine plus infection-induced antibodies was observed for omicron variant which might explain immune escape. FUNDING Department of Biotechnology, India; Bill & Melinda Gates Foundation, USA.
Collapse
Affiliation(s)
| | - Gaurav Batra
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | | | | | - Souvick Chattopadhyay
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Bhabatosh Das
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Mudita Gosain
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Ayushi
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Janmejay Singh
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Anantharaj Anbalagan
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Heena Shaman
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Kamal Pargai
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Farha Mehdi
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Soon Jyoti Das
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Namrata Kahlon
- ESIC Medical College and Hospital, Faridabad, Haryana, India
| | - Savita Singh
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Pallavi Kshetrapal
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Nitya Wadhwa
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Anil K Pandey
- ESIC Medical College and Hospital, Faridabad, Haryana, India
| | - Shinjini Bhatnagar
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Pramod Kumar Garg
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
| |
Collapse
|
2
|
Hingankar N, Deshpande S, Das P, Rizvi ZA, Wibmer CK, Mashilo P, Ansari MY, Burns A, Barman S, Zhao F, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Dandotiya J, Bhattacharyya S, Mani S, Samal S, Singh S, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshi G, Ward AB, Bhatnagar S, Awasthi A, Sok D, Bhattacharya J. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathog 2022; 18:e1010465. [PMID: 35482816 PMCID: PMC9089897 DOI: 10.1371/journal.ppat.1010465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 05/10/2022] [Accepted: 03/24/2022] [Indexed: 12/23/2022] Open
Abstract
Although efficacious vaccines have significantly reduced the morbidity and mortality of COVID-19, there remains an unmet medical need for treatment options, which monoclonal antibodies (mAbs) can potentially fill. This unmet need is exacerbated by the emergence and spread of SARS-CoV-2 variants of concern (VOCs) that have shown some resistance to vaccine responses. Here we report the isolation of five neutralizing mAbs from an Indian convalescent donor, out of which two (THSC20.HVTR04 and THSC20.HVTR26) showed potent neutralization of SARS-CoV-2 VOCs at picomolar concentrations, including the Delta variant (B.1.617.2). One of these (THSC20.HVTR26) also retained activity against the Omicron variant. These two mAbs target non-overlapping epitopes on the receptor-binding domain (RBD) of the spike protein and prevent virus attachment to its host receptor, human angiotensin converting enzyme-2 (hACE2). Furthermore, the mAb cocktail demonstrated protection against the Delta variant at low antibody doses when passively administered in the K18 hACE2 transgenic mice model, highlighting their potential as a cocktail for prophylactic and therapeutic applications. Developing the capacity to rapidly discover and develop mAbs effective against highly transmissible pathogens like coronaviruses at a local level, especially in a low- and middle-income country (LMIC) such as India, will enable prompt responses to future pandemics as an important component of global pandemic preparedness.
Collapse
Affiliation(s)
- Nitin Hingankar
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Suprit Deshpande
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Payel Das
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Zaigham Abbas Rizvi
- Immuno-biology Lab, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- Immunology Core, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Constantinos Kurt Wibmer
- National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
| | - Poppy Mashilo
- National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
| | - Mohammed Yousuf Ansari
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Alison Burns
- Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America
- IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America
| | - Shawn Barman
- Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America
- IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America
| | - Fangzhu Zhao
- Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America
- IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America
| | - Sohini Mukherjee
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- IAVI, New York, United States of America
- IAVI, New Delhi, India
| | - Jonathan L. Torres
- Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America
- IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America
| | - Souvick Chattopadhyay
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Farha Mehdi
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Jyoti Sutar
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- IAVI, New York, United States of America
- IAVI, New Delhi, India
| | - Deepak Kumar Rathore
- Immunology Core, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Kamal Pargai
- Bioassay laboratory, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Janmejay Singh
- Bioassay laboratory, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Sudipta Sonar
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Kamini Jakhar
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Jyotsna Dandotiya
- Immuno-biology Lab, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- Immunology Core, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Sankar Bhattacharyya
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Shailendra Mani
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Sweety Samal
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Savita Singh
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Pallavi Kshetrapal
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | | | - Gaurav Batra
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Guruprasad Medigeshi
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- Bioassay laboratory, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Andrew B. Ward
- Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America
- IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America
| | - Shinjini Bhatnagar
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Amit Awasthi
- Immuno-biology Lab, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- Immunology Core, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
| | - Devin Sok
- Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America
- IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America
- IAVI, New York, United States of America
| | - Jayanta Bhattacharya
- IAVI HIV Vaccine Translational Research Laboratory, IAVI-THSTI partnership program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India
- IAVI, New York, United States of America
- IAVI, New Delhi, India
| |
Collapse
|
3
|
Dash L, Subramaniam S, Khulape SA, Prusty BR, Pargai K, Narnaware SD, Patil NV, Pattnaik B. Development and Utilization of VHH Antibodies Derived from Camelus Dromedarius Against Foot-and-Mouth Disease Virus. Anim Biotechnol 2018. [PMID: 29527970 DOI: 10.1080/10495398.2018.1433191] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Foot-and-mouth disease (FMD) is an acute, highly contagious, and economically devastating viral disease of domestic and wildlife species. For effective implementation of FMD control program, there is an imperative need for developing a rapid, sensitive, and specific diagnostics which help in the identification of serotypes involved in the outbreaks. The humoral immune response of the Camelidae is unique since in these animals 75% of circulating antibodies are constituted by heavy-chain antibodies and 25% are conventional immunoglobulin with two identical heavy chains. In the present study, we developed and characterized FMD virus-specific single-domain heavy-chain antibodies (VHHs) against inactivated whole-virus antigens of FMDV serotypes O (INDR2/1975), A (IND40/2000), and Asia 1 (IND63/1972) vaccine strains. After six rounds of panning and enrichment, these VHHs were stably expressed in Escherichia coli cells. The VHHs directed against outer capsid proteins of FMD virus were successfully utilized as the capture antibody in liquid-phase blocking ELISA (LPBE) thus replacing rabbit coating antibodies. Our study demonstrated the utility of FMD virus-specific VHHs as potential candidates in FMD research and diagnostic application.
Collapse
Affiliation(s)
- Lipsa Dash
- a ICAR-Directorate on Foot and Mouth Disease , Mukteswar , Nainital, Uttarakhand , India
| | - Saravanan Subramaniam
- a ICAR-Directorate on Foot and Mouth Disease , Mukteswar , Nainital, Uttarakhand , India
| | - Sagar A Khulape
- a ICAR-Directorate on Foot and Mouth Disease , Mukteswar , Nainital, Uttarakhand , India
| | - Bikash Ranjan Prusty
- a ICAR-Directorate on Foot and Mouth Disease , Mukteswar , Nainital, Uttarakhand , India
| | - Kamal Pargai
- a ICAR-Directorate on Foot and Mouth Disease , Mukteswar , Nainital, Uttarakhand , India
| | - Shirish D Narnaware
- b ICAR-National Research Center on Camel , Jorbeer, Bikaner , Rajasthan , India
| | - Niteen V Patil
- b ICAR-National Research Center on Camel , Jorbeer, Bikaner , Rajasthan , India
| | - Bramhadev Pattnaik
- a ICAR-Directorate on Foot and Mouth Disease , Mukteswar , Nainital, Uttarakhand , India
| |
Collapse
|